Influence of Different Regimens of Prostate Cancer Androgen Deprivation on Metabolic Syndrome and Sexual Dysfunction
https://doi.org/10.18027/2224-5057-2015-4-48-51
Abstract
Androgen deprivation remains a golden standard therapy in advance Prostate cancer. Besides adequate suppression of the tumor growth, ADT causes temporary or even permanent sexual dysfunction along with the high risk of metabolic complications. In our prospective study we have included 56 patients with advanced forms of prostrate cancer and remained sexual activity whom were subjects to different regimens of ADT. The primary goal of our study was evaluation of the degree of metabolic complications and time to regain sexual activity using continuous and intermittent GnRH analogues therapy and sequential therapy with GnRH analogues and bicalutamide.
About the Authors
Sergey Vladimirovich Mishugin
Moscow City Hospital 57
Russian Federation
Russian Federation
MD, PhD, chief of the department of oncological urology,
Moscow
Aleksandr Anatol’evich Gritzkevich
Moscow Insitute of Surgery named after A.V. Vishnevsky
Russian Federation
Russian Federation
MD, PhD, department of urology,
Moscow
Anton Aleksandrovich Kosov
Moscow Research Institute of Urology named after N.A. Lopatkin
Russian Federation
Russian Federation
MD, department of oncological urology,
Moscow
Igor' Georgievich Rusakov
Moscow Research Institute of Oncology named after P.A. Gertzen
Russian Federation
Russian Federation
MD, PhD, DSc, professor, department of oncological urology,
Moscow
References
1. SEER: Surveillance, Epidemiology and End Results (SEER): Stat Fact Sheets: Prostate Cancer 2008.
2. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G et al: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337: 295.
3. D’Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A and Kantoff PW: 6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004; 292: 821.
4. Walsh PC: Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. J Urol 1997; 158: 1623.
5. F. J. Fowler Jr., M.M. Collins., E.W. Corkery, D.B. Elliot, and M. J. Barry, “ The impact of Androgen Deprivation on Quality of Life after radical Prostatectomy for prostate carcinoma” Cancer, vol. 95, no.2, pp. 287–295, 2002.
6. Peter Iversen, Chris J Tyrrell, Amir V Kaisary et al. “Bicalutamide Monotherapy Compared with Castration in Patients with Nonmetastatic Locally Advanced prostate Cancer: 6.3 years of Followup” The Journal of Urology 2000 DOI: http://dx.doi.org/10.1016/S0022–5347(05)67032–2.
Review
For citations:
Mishugin S.V., Gritzkevich A.A., Kosov A.A., Rusakov I.G. Influence of Different Regimens of Prostate Cancer Androgen Deprivation on Metabolic Syndrome and Sexual Dysfunction. Malignant tumours. 2015;(4):48-51. (In Russ.) https://doi.org/10.18027/2224-5057-2015-4-48-51
Views:
1046
Email this article 